Allergy Therapeutics plc (AGY) Price Target Raised to GBX 46
Allergy Therapeutics plc (LON:AGY) had its price objective hoisted by equities researchers at FinnCap from GBX 43 ($0.56) to GBX 46 ($0.60) in a report released on Tuesday. The brokerage currently has a “buy” rating on the stock. FinnCap’s target price suggests a potential upside of 78.64% from the company’s previous close.
A number of other equities research analysts also recently weighed in on AGY. Stifel Nicolaus reissued a “buy” rating and set a GBX 60 ($0.78) price target on shares of Allergy Therapeutics plc in a research note on Tuesday, April 4th. Numis Securities Ltd boosted their price target on shares of Allergy Therapeutics plc from GBX 37 ($0.48) to GBX 45 ($0.59) and gave the stock a “buy” rating in a research note on Tuesday, April 4th. Finally, Panmure Gordon reissued a “buy” rating and set a GBX 53 ($0.69) price target on shares of Allergy Therapeutics plc in a research note on Thursday, April 20th.
Shares of Allergy Therapeutics plc (LON AGY) opened at 25.75 on Tuesday. Allergy Therapeutics plc has a one year low of GBX 17.25 and a one year high of GBX 31.00. The company’s market capitalization is GBX 152.81 million. The company’s 50-day moving average is GBX 26.26 and its 200-day moving average is GBX 25.56.
ILLEGAL ACTIVITY WARNING: “Allergy Therapeutics plc (AGY) Price Target Raised to GBX 46” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/07/18/allergy-therapeutics-plc-agy-price-target-raised-to-gbx-46.html.
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.